From 0.1% to 0.7% of patients using ACE inhibitors can develop life-threatening adverse effect, angioedema, which is characterized as nonallergic, because it is not associated with degranulation of mast cells by immunoglobulin-E.[3] Angioedema can present in different body locations, for example, face, lips, tongue, throat, and viscera.[4,5] Upper respiratory tract involvement may lead to airway obstruction and acute respiratory distress if not recognized from the beginning.[6]. This evidence concerns the gene ACE and angioedema.